Videos

Bispecific antibodies are currently approved as late-line therapy, but they are moving up to earlier lines “as they prove their worth, so to speak,” said Adams. She discussed the efficacy, route of administration, dosing mechanism of action, and the various tradeoffs among the four bispecific antibodies that the FDA has approved: teclistamab, elranatamab, talquetamab and linvoseltamab.

In this clip, Lindsay Greenleaf, J.D., MBA, discusses the latest news concerning the 340B Drug Pricing Program, calling out what she believes is “abuse” within the program.

Provider groups, especially community oncologists, are worried that drug prices negotiated under the IRA will drastically reduce their buy-and-bill revenue from administering drugs. Lindsay Greenleaf, J.D., MBA, discusses drugmaker rebates to the federal government as a way to allay their fears.

ADVI Health’s Lindsay Greenleaf discusses how most-favored-nation drug pricing is playing out among specialty drugs.

In this episode, Optimizing Immunotherapy Selection and Safety Management in NSCLC, the panelists explore the following questions: How are you deciding between available immunotherapies in NSCLC, both as monotherapies and in combination with chemotherapy? What are your current protocols for monitoring and managing adverse events associated with immunotherapies? Does the consistent adverse event profile with cemiplimab plus chemotherapy over 5 years increase this regimen’s clinical value?

A pharmacist-led specialty pharmacy care model presented at AXS26 shows improved A1C control, fewer hospital visits and lower total costs by expanding support beyond medications to include lifestyle, social needs and care coordination for high-risk patients.

A specialty pharmacy model presented at AXS26 shows how expanding pharmacist roles into care management can improve outcomes and support shared savings in value-based care.

In this clip, Mike Ciarametaro, managing director of policy at Avalere Health, explains all the “moving pieces” that could affect the health policy landscape in the coming months.

Ahead of Asembia’s 2026 Specialty Pharmacy Summit, Avalere Health's Mina Allo and Mike Ciarametaro discussed the potential impact of PBM reform on the employer market and the likelihood of partisan legislative gridlock ahead of the upcoming elections.

In Emerging Role of Oral JAK Inhibition in Vitiligo Management, Dr. Desai delves into the following critical questions:

Bispecific antibodies are highly efficacious and have a milder side effect profile than other late-line treatments for multiple myeloma, according to Adams.

Multiple myeloma accounts for only 1.8% of cancers, but it is the second-most common blood cancer, with approximately 36,000 new cases diagnosed each year in the U.S., says Adams. The number of treatment choices has proliferated as new innovative therapies, such as the bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy, have been developed.

Learn how continuous glucose monitors fit school, work, and hospitals, reducing finger sticks, improving sleep, and clarifying alarm options.

See how 2026 ADA guidance broadens CGM use beyond insulin, urges payer coverage, and highlights kids, pregnancy, and older adults at risk.

This episode, titled Interpreting EMPOWER-Lung 3: Key Endpoints and Confidence in Cemiplimab-Based Therapy, features lung cancer experts answering the following critical questions: What are your main takeaways from the data covered? Which of the endpoints examined are most important for your clinical practice and why? Does the consistent benefit with cemiplimab plus chemotherapy across the different subgroups increase your confidence?

In this episode, Long-Term Repigmentation Outcomes and Real-World Use of Ruxolitinib Cream, Dr. Desai explores the following questions:

At the AMCP Annual Meeting this week, experts from Prime Therapeutics said virtual navigation and clinical pathways are helping lower acute care use, guide treatment decisions and improve outcomes for patients with cancer.

In this interview, Luis Ortiz, M.D., explains the current and emerging therapies for narcolepsy type 1 treatment.

In this interview, Luis Ortiz, M.D., explains how burdensome a narcolepsy diagnosis can be for a patient and why listening to their experiences helps shape new guidelines and treatments.

Julie Kendle, Pharm.D., senior director of clinical pharmacy at IPD Analytics, explains how managed care organizations can support patients at risk of HIV.

Brian MacDonald, Pharm.D., of Prime Therapeutics discusses the low utilization of the gene therapies for hemophilia. Pfizer and BioMarin have pulled their FDA-approved hemophilia gene therapies from the market, citing low demand.

Pfizer and BioMarin have pulled their hemophilia gene therapies, citing low demand.

As CAR-T therapy expands into earlier stages of treatment and new care settings, payers are weighing access, cost savings and utilization management strategies.

See how continuous glucose monitors replace painful finger sticks, deliver real-time alerts, and help prevent dangerous highs and lows.

CGM delivers real-time glucose trends and alerts, enabling personalized diet changes, fewer fingersticks, and proactive care that can reduce medications, complications, and costs.

In this interview, Luis Ortiz, M.D., explains how narcolepsy type 1 is now diagnosed and how it differs from type 2.